glp 1 covered by blue cross blue shield of MA to widely stop covering weight loss drugs Does Blue Cross Blue Shield
Description
health system nearly $173B a year
There is currently no strong evidence to support or rule out GLP-1s causing diseases like pancreatic or thyroid cancer
They are also more readily available during shortages
All prescription weight loss medications, including GLP-1 agonists like Wegovy and Saxenda, require a valid prescription and ongoing medical supervision
It will grow from $4.21 billion in 2025 to $5.96 billion in 2026 at a compound annual growth rate (CAGR) of 41.8%
